Display options
Cite
Kiruthiga KG, Ramakrishna B, Saha S, et al. Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. J Gastrointest Oncol. 2018;9(2):326-337doi: 10.21037/jgo.2018.01.08.
Kiruthiga, K. G., Ramakrishna, B., Saha, S., & Sen, S. (2018). Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. Journal of gastrointestinal oncology, 9(2), 326-337. https://doi.org/10.21037/jgo.2018.01.08
Kiruthiga, Kala Gnanasekaran, et al. "Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival." Journal of gastrointestinal oncology vol. 9,2 (2018): 326-337. doi: https://doi.org/10.21037/jgo.2018.01.08
Kiruthiga KG, Ramakrishna B, Saha S, Sen S. Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. J Gastrointest Oncol. 2018 Apr;9(2):326-337. doi: 10.21037/jgo.2018.01.08. PMID: 29755772; PMCID: PMC5934143.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2018 Apr;9(2):326-337. doi: 10.21037/jgo.2018.01.08.

Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival.

Journal of gastrointestinal oncology

Kala Gnanasekaran Kiruthiga, Banumathi Ramakrishna, Soumitra Saha, Sudipta Sen

Affiliations

  1. Departments of Pathology, Christian Medical College, Vellore, India.
  2. Paediatric Surgery, Christian Medical College, Vellore, India.

PMID: 29755772 PMCID: PMC5934143 DOI: 10.21037/jgo.2018.01.08

Abstract

BACKGROUND: Hepatoblastoma (HB) has different histological subtypes, with varying prognosis. Though the survival has drastically improved, subsets of patients are not responsive to therapy. Therefore, it becomes important to determine the factors which affect the behaviour of the tumour. This study was aimed to look at the histopathological subtypes and compare with immunohistochemical (IHC) expression of CK19, beta-catenin and EpCAM and survival.

METHODS: This study included 55 cases of HB. IHC expression of CK19, beta-catenin and EpCAM were correlated with histological subtypes, tumour behaviour, response to chemotherapy and survival.

RESULTS: Most common epithelial subtype was fetal (43.2%) and mixed epithelial (54.8%) in pre- and post-chemotherapy groups respectively. Microvascular invasion (MVI) was present in 14/33 resected tumours. CK19 expression was seen in 54.2% and 72.2% of embryonal subtype, nuclear beta-catenin expression in 48.7% and 57.1% and EpCAM in 100% and 82.1% of tumours in pre- and post-chemotherapy groups, respectively. Fetal subtype had a lesser chance of MVI, recurrence, metastasis and death. Beta-catenin expression was associated with lower event free survival (EFS) and EpCAM with ≥50% viable tumour following chemotherapy (P=0.04). Age at diagnosis ≤2 years, male sex, alpha-fetoprotein <10,000 IU/mL following chemotherapy, solitary tumour (P=0.001), size ≤5 cm, pretreatment extent of disease (PRETEXT) I&II, mitosis ≤2/10 high power fields (hpf), viable tumour <50% (P=0.04) and absent nuclear expression of beta-catenin, predicted a higher EFS rate.

CONCLUSIONS: Beta-catenin expression is associated with lower EFS and EpCAM expression with tumour viability. Multifocality and viable tumour ≥50% were significant factors predicting lower EFS. These factors should be included in the prognostication of HBs.

Keywords: Beta-catenin; CK19; EpCAM; chemotherapy

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. J Pediatr Surg. 2004 Dec;39(12):1775-8 - PubMed
  2. Eur J Surg Oncol. 2014 Nov;40(11):1533-9 - PubMed
  3. Cancer. 2003 Aug 15;98(4):668-78 - PubMed
  4. Oncologist. 2000;5(6):445-53 - PubMed
  5. Semin Diagn Pathol. 1994 May;11(2):136-43 - PubMed
  6. Appl Immunohistochem Mol Morphol. 2017 Feb 9;:null - PubMed
  7. Liver Int. 2010 Jan;30(1):102-11 - PubMed
  8. Cancer. 1970 Mar;25(3):551-63 - PubMed
  9. Pediatr Blood Cancer. 2014 Sep;61(9):1593-7 - PubMed
  10. Zhonghua Er Ke Za Zhi. 2015 Feb;53(2):119-23 - PubMed
  11. Int J Cancer. 1997 Dec 19;74(6):593-9 - PubMed
  12. Eur J Cancer. 2012 Aug;48(12):1853-9 - PubMed
  13. Lancet Oncol. 2017 Jan;18(1):122-131 - PubMed
  14. Oncoimmunology. 2013 Jan 1;2(1):e22620 - PubMed
  15. J Pathol. 1999 Jun;188(2):201-6 - PubMed
  16. Cancer. 2000 Oct 15;89(8):1845-53 - PubMed
  17. Cancer. 2002 Jul 1;95(1):172-82 - PubMed
  18. Pediatr Blood Cancer. 2009 Dec;53(6):1016-22 - PubMed
  19. J Pediatr Surg. 2012 Jul;47(7):1331-9 - PubMed
  20. Pediatr Radiol. 2014 Oct;44(10):1275-80 - PubMed
  21. J Pediatr Hematol Oncol. 2012 Nov;34(8):e320-8 - PubMed
  22. Cancer. 1985 Oct 1;56(7):1636-42 - PubMed
  23. Virchows Arch A Pathol Anat Histopathol. 1985;407(4):387-405 - PubMed
  24. Pediatr Pathol. 1992 Mar-Apr;12(2):167-83 - PubMed
  25. J Formos Med Assoc. 2017 Jul;116(7):549-553 - PubMed
  26. Eur J Cancer. 2012 Jul;48(10):1543-9 - PubMed
  27. Semin Pediatr Surg. 2012 Feb;21(1):21-30 - PubMed
  28. J Pediatr Surg. 2013 Dec;48(12):2474-8 - PubMed
  29. Eur J Cancer. 1994;30A(8):1052-8 - PubMed
  30. Am J Surg Pathol. 2010 Mar;34(3):287-99 - PubMed
  31. Indian J Med Res. 2015 Oct;142(4):391-8 - PubMed
  32. HPB (Oxford). 2013 Oct;15(10):741-6 - PubMed
  33. J Clin Oncol. 2011 Aug 20;29(24):3301-6 - PubMed
  34. Hum Pathol. 1987 Oct;18(10):1025-35 - PubMed
  35. Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):857-74 - PubMed
  36. Ultrasound Obstet Gynecol. 2000 Jul;16(1):94-7 - PubMed
  37. J Clin Pathol. 2011 May;64(5):415-20 - PubMed
  38. Pathol Res Pract. 2013 Sep;209(9):568-73 - PubMed
  39. Cancer. 2001 Dec 15;92(12):3130-4 - PubMed
  40. Cancer. 2002 Feb 15;94(4):1111-20 - PubMed
  41. Pediatr Dev Pathol. 2005 Jul-Aug;8(4):435-47 - PubMed
  42. Pediatr Transplant. 2012 Sep;16(6):549-63 - PubMed
  43. J Pediatr Surg. 2004 May;39(5):721-5 - PubMed
  44. J Pathol. 2000 May;191(1):102-3 - PubMed
  45. J Pathol. 2001 Apr;193(4):483-90 - PubMed

Publication Types